You are here:Home-Research Areas-Neurological Disease-Alzheimer Disease

Request The Product List ofAlzheimer Disease Alzheimer Disease

Cat. No. Product Name CAS No. Information
PC-62602

ALZ-801

1034190-08-3

ALZ-801 is an orally available, valine-conjugated prodrug of tramiprosate, a small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor for the treatment of Alzheimer's disease.

Alzheimer Disease

Phase 3 Clinical

PC-61522

SUVN-502 mesylate hydrate

1791396-45-6

SUVN-502 (SUVN502) is a potent, selective, brain penetrant and orally active 5-HT6 receptor antagonist with Ki of 2.04 nM; shows high selectivity over 5-HT2A receptor and other 100 target sites; produces synergistic effects in extracellular levels of acetylcholine in the ventral hippocampus combined with donepezil and memantine; shows potential for treatment of Alzheimer's disease.

Alzheimer Disease

Phase 2 Clinical

PC-61521

SUVN-502 mesylate

1791396-46-7

SUVN-502 (SUVN502) is a potent, selective, brain penetrant and orally active 5-HT6 receptor antagonist with Ki of 2.04 nM; shows high selectivity over 5-HT2A receptor and other 100 target sites; produces synergistic effects in extracellular levels of acetylcholine in the ventral hippocampus combined with donepezil and memantine; shows potential for treatment of Alzheimer's disease.

Alzheimer Disease

Phase 2 Clinical

PC-61500

SUVN-502

701205-60-9

SUVN-502 (SUVN502, Masupirdine) is a potent, selective, brain penetrant and orally active 5-HT6 receptor antagonist with Ki of 2.04 nM; shows high selectivity over 5-HT2A receptor and other 100 target sites; produces synergistic effects in extracellular levels of acetylcholine in the ventral hippocampus combined with donepezil and memantine; shows potential for treatment of Alzheimer's disease.

Alzheimer Disease

Phase 2 Clinical

PC-60809

Sembragiline

676479-06-4

Sembragiline (RO4602522, RG1577, EVT 302) is a novel potent, selective, orally available monoamine oxidase B (MAO-B) inhibitor with IC50 of 5.9 nM, >600-fold selectivity over MAO-A; displays no affinity for more than 100 different receptors, enzymes and ion channels; protects against neuronal loss and reduces both ROS formation and reactive astrogliosis in transgenic animal model conditionally overexpressing MAO-B in astroglia, exhibits potential for treatment of Alzheimer's disease (AD) and other neurodegenerative disorders.

Alzheimer Disease

Phase 2 Clinical

PC-60394

PQ-912

1276021-65-8

PQ-912 (PQ 912, PQ912) is a potent glutaminyl cyclase (QC) inhibitor that inhibits human, rat, and mouse QC with Ki of 20-65 nM; shows a favourable profile of the compound for QC engagement coupled to a reduction of pE-Aβ and behavioural improvementsthe first in class inhibitor of glutaminyl cyclases currently being in clinical development for Alzheimer's disease.

Alzheimer Disease

Phase 2 Clinical

PC-60371

UE2343

1346013-80-6

UE2343 (UE-2343, Xanamem) is a potent, orally bioavailable, brain penetrant 11β-HSD1 inhibitor with IC50 of 24 nM in cell-free assays, with no activity for isozyme 11β-HSD2; displays a superior preclinical profile for further development, and shows potential for cognitive impairment in early Alzheimer's disease (AD).

Alzheimer Disease

Phase 2 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com